Navigation Links
Pro-Dex, Inc. Announces Fiscal 2011 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast
Date:9/8/2011

IRVINE, Calif., Sept. 8, 2011 /PRNewswire/ -- PRO-DEX, INC. (Nasdaq: PDEX) invites investors and analysts to listen to a broadcast review of the Company's fiscal 2011 fourth quarter and full-year financial results.

The conference call is scheduled to be broadcast live over the internet on Wednesday, September 14, 2011 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) and may be accessed by visiting the Company's website at www.pro-dex.com and selecting the "Investor Relations" page. The conference call may also be accessed at www.InvestorCalendar.com. Investors and analysts who would like to participate in the conference call may do so via telephone at (877) 407-8033, or at (201) 689-8033 if calling from outside the U.S.

For those who cannot access the live broadcast, a replay will be available from approximately two hours after the completion of the call until midnight (Eastern Time) on September 28, 2011 by calling (877) 660-6853, or (201) 612-7415 if calling from outside the U.S., and then entering account number 286 and conference I.D. number 378851. An online archive of the broadcast will be available on the Company's website at www.pro-dex.com, on the "Investor Relations" page, for a period of 365 days.

Pro-Dex, Inc., with operations in California, Oregon and Nevada, specializes in bringing speed to market in the development and manufacture of technology-based solutions that incorporate powered surgical device drive systems, embedded motion control and fractional horsepower DC motors, serving the medical, dental, semi-conductor, scientific research and aerospace markets. Pro-Dex's products are found in hospitals, dental offices, medical engineering labs, commercial and military aircraft, scientific research facilities and high tech manufacturing operations around the world. For more information, visit the Company's website at www.pro-dex.com.

Statements herein concerning the Company's plans, growth and strategies may include 'forward-looking statements' within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. The Company's actual results may differ materially from those suggested as a result of various factors. Interested parties should refer to the disclosure concerning the operational and business concerns of the Company set forth in the Company's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Pro-Dex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement
2. Pro-Dex, Inc. Announces Fiscal Second Quarter 2010 Results
3. Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customers Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders
4. Pro-Dex, Inc. Announces Fiscal 2010 Third Quarter Financial Results Conference Call and Webcast
5. Pro-Dex, Inc. Appoints Harold A. Hurwitz as Chief Financial Officer
6. Pro-Dex, Inc. Announces Fiscal Second Quarter and Six Month Results
7. Pro-Dex, Inc. Announces Fiscal 2011 Third Quarter Financial Results Conference Call and Webcast
8. Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... 2016  Axovant Sciences Ltd. (NYSE: ... on the treatment of dementia, today announced a ... 2b trial evaluating treatment with intepirdine (RVT-101), combined ... plus placebo in people with mild-to-moderate Alzheimer,s disease. ... to treatment was associated with reduced progression in ...
(Date:12/8/2016)... LONDON , Dec. 8, 2016 Australia ... GlobalData,s new report, "Australia Ophthalmic Lasers Market Outlook to ... Lasers market. The report provides value, in millions of ... within market segements - Excimer Lasers, Femtosecond Lasers and ... and distribution shares data for each of these market ...
(Date:12/8/2016)... 2016  The global biosurgery market is expected to ... period of 2016 to 2021. The market is poised ... 18.21 billion in 2016. The market is primarily driven ... related injuries and spinal problems, increasing clearance of biosurgery ... blood loss management. In this report, the ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... Groth Family ... Pasco and Richland, is initiating a charity drive to support the family of ... recent automobile collision. , On October 29th of this year, Cindy Hendrickson ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... its 10th anniversary with the grand opening of the Sober College Robert Pfeifer ... spanned two days, December 2-3, and was attended by an overwhelming amount of ...
(Date:12/9/2016)... ... December 09, 2016 , ... "I had a terrible time trying to get ... thought that if the nebulizer had a more child-friendly design, then children would be ... developed the patent-pending NEBY to avoid the need to deliver medication via a nebulizer ...
(Date:12/8/2016)... Pennsylvania (PRWEB) , ... December 08, 2016 , ... ... Duck Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which ... , “This was our first franchise-wide Quack Gives Back initiative, ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...
Breaking Medicine News(10 mins):